Bacterial polysaccharide-protein conjugate vaccines

British Medical Bulletin

Volumn 70, Issue , 2004, Pages 1-14

  Finn, Adam ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; NEIS VAC C; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; POLYRIBOSYL RIBITOL PHOSPHATE; TETANUS TOXOID; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CONJUGATION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LOWER RESPIRATORY TRACT INFECTION; MUCOSAL IMMUNITY; NASOPHARYNX; NEISSERIA MENINGITIDIS; NEWBORN INFECTION; OTITIS MEDIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHI; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; PREGNANCY; SALMONELLA VACCINES; STREPTOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 11244266086     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/ldh021     Document Type: Review

References (63)

1. Wilson CB, Lewis DB, Penix LA. The physiologic immunodeficiency of immaturity. In: Stiehm ER (ed) Immunologic Disorders in Infants and Children, 4th edn. Philadelphia, PA: W.B. Saunders, 1996: 253-95
2. Press JL. Neonatal immunity and somatic mutation. Int Rev Immunol 2000; 19: 265-87
3. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001; 19: 3331-46
4. Bondada S, Wu H, Robertson DA, Chelvarajan RL. Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine 2000; 19: 557-65
5. Zhang Q, Choo S, Everard J, Jennings R, Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000; 68: 2692-7
6. Nieminen T, Kayhty H, Virolainen A, Eskola J. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1998; 16: 313-9
7. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000; 176: 154-70
8. Musher DM, Groover JE, Watson DA et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Invest Med 1997; 45: 57-68
9. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178: 870-4
10. Wessels MR. Regulation of virulence factor expression in group A streptococcus. Trends Microbiol 1999; 7: 428-30
11. Wyle FA, Artenstein MS, Brandt BL et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126: 514-21
12. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138: 4402-7
13. Koskela M, Leinonen M, Haiva VM, Timonen M, Makela PH. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986; 5: 45-50
14. Avery OT, Geobel WF. Chemo-immunological studies on conjugated carbohydrate-proteins. II Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50: 533-50
15. Granoff DM, Suarez BK, Pandey JP, Shackelford PG. Genes associated with the G2m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 1988; 157: 1142-9
16. Weinberg GA, Granoff DM. Immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children with conditions associated with impaired antibody responses to type b polysaccharide vaccine. Pediatrics 1990; 85: 654-61
17. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310: 1561-6
18. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340: 592-4
19. Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999; 17 (Suppl 2): S28-S36
20. Bell F, Martin A, Blondeau C, Thornton C, Chaplais J, Finn A. Combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child 1996; 75: 298-303
21. Perez-Melgosa M, Ochs HD, Linsley PS et al. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur J Immunol 2001; 31: 2373-81
22. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120: 184-9
23. Eskola J, Kayhty H, Takala AK et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-7
24. Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. N Engl J Med 1990; 323: 1393-401
25. Bell F, Heath P, Shackley F et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 1998; 16: 637-42
26. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 1999; 354: 2063-8
27. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188: 481-5
28. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361: 1521-3
29. Takala AK, Santosham M, Almeido-Hill J et al. Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993; 12: 593-9
30. Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993; 167: 1320-9
31. Granoff DM, Kelsey SK, Bijlmer HA et al. Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Clin Diagn Lab Immunol 1995; 2: 574-82
32. Rappuoli R. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 2001; 19: 2319-22
33. Ramsay M, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup c conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6
34. Richmond P, Borrow R, Findlow J et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunological priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 2001; 69: 2378-88
35. Maiden MC, Stuart JM, The UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829-31
36. Zhang Q, Lakshman R, Burkinshaw R et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect Immun 2001; 69: 4337-41
37. Zhang Q, Pettitt E, Burkinshaw R, Race G, Shaw L, Finn A. Mucosal immune responses to meningococcal conjugate polysaccharide vaccine in infants. Pediatr Infect Dis J 2002; 21: 209-13
38. Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180: 1894-901
39. Artenstein MS, Brandt BL. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J Immunol 1975; 115: 5-7
40. Borrow R, Southern J, Andrews N et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001; 19: 3043-50
41. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95
42. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9
43. Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37: 1155-64
44. Klugman KP, Madhi SA, Huebner RE et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-8
45. O'Brien KL, Moulton LH, Reid R et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362: 355-61
46. Choo S, Finn A. New pneumococcal vaccines for children. Arch Dis Child 2001; 84: 289-94
47. Choo S, Zhang Q, Seymour L, Akhtar S, Finn A. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 2000; 182: 1260-3
48. Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine PncCRM. Pediatr Infect Dis J 2001; 20: 25-33
49. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180: 1171-6
50. Dagan R, Fraser D. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr Infect Dis J 2000; 19: S79-S88
51. Murdoch C, Lakshman R, Burkinshaw R, Shaw L, Finn A. Effect of heptavalent conjugate pneumococcal vaccine in infancy and booster polysaccharide vaccine at 13 months on nasopharyngeal carriage of S. pneumoniae in children aged 2 to 4 years. Clin Infect Dis 2001; 33: 1148
52. Gherardi G, Inostrozo JS, O'Ryan M et al. Genotypic survey of recent beta-lactam-resistant pneumococcal nasopharyngeal isolates from asymptomatic children in Chile. J Clin Microbiol 1999; 37: 3725-30
53. Whitney CG, Parley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46
54. Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000; 19 (Suppl 1): S87-S95
55. Schrag SJ, Zywicki S, Farley MM et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342: 15-20
56. Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child 2003; 88: 375-8
57. Lin FY, Ho VA, Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263-9
58. Cryz Jr SJ, Lang A, Rudeberg A et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt 1997; 345-9
59. Cryz SJ, Que JO, Cross AS, Purer E. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine. Vaccine 1995; 13: 449-53
60. Tollersrud T, Zernichow L, Andersen SR, Kenny K, Lund A. Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle. Vaccine 2001; 19: 3896-903
61. Shen X, Lagergard T, Yang Y et al. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. Vaccine 2001; 19: 3360-8
62. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 1999; 67: 5892-7
63. Finn A, Zhang Q, Seymour L, Fasching C, Pettitt E, Janoff EN. Induction of functional secretory IgA responses in breast milk by pneumococcal capsular polysaccharides. J Infect Dis 2002; 186: 1422-9